Filing Details
- Accession Number:
- 0001651308-20-000094
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2020-07-09 16:43:10
- Reporting Period:
- 2020-07-07
- Accepted Time:
- 2020-07-09 16:43:10
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1651308 | Beigene Ltd. | BGNE | Pharmaceutical Preparations (2834) | 981209416 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1683913 | Jane Huang | C/O Mourant Governance Services (Cayman) 94 Solaris Avenue Camana Bay, Grand Cayman E9 KY1-1108 | Cmo, Hematology | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
American Depositary Shares | Acquisiton | 2020-07-07 | 3,921 | $160.40 | 3,921 | No | 4 | M | Direct | |
American Depositary Shares | Disposition | 2020-07-07 | 3,921 | $200.00 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Ordinary Shares | Share Option (Right to Buy) | Disposition | 2020-07-07 | 50,973 | $0.00 | 50,973 | $12.34 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
232,180 | 2028-06-25 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
---|---|---|---|
Ordinary Shares | 326,247 | Direct |
Footnotes
- Each American Depositary Share represents 13 Ordinary Shares.
- The sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 11, 2019.
- The number of securities underlying each option and the exercise price therefor are represented in ordinary shares.
- These securities vest over a four-year period as follows: 25% on June 26, 2019, and the remaining in 36 successive equal monthly installments, subject to continued service. Unvested shares are subject to accelerated vesting upon certain termination events following a change in control.